Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim Bone Marrow Morphology Study in ITP
NCT00907478Phase 4Completed
- Sponsor
- Amgen
- Start
- Aug 2009
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Amgen. Primary endpoint: Percentage of Participants With Collagen Fibrosis at 3 years. Started Aug 2009; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00907478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00907478.